Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798421 | 1.00 | LMNA (0.41) | LMNANPSR1KDM4ESMN1; SMN2HTT | |
| SCHEMBL22327661 | 0.83 | CACNA1F (0.39) | LMNANPSR1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL14865109 | 0.76 | MEN1 (0.40) | TRPM8 | |
| SCHEMBL3637292 | 0.75 | NPC1 (0.47) | L3MBTL1 | |
| SCHEMBL3408775 | 0.73 | ALOX5 (0.41) | KDM4ETRPM8ALDH1A1 | |
| SCHEMBL3408769 | 0.73 | ALOX5 (0.41) | KDM4ETRPM8ALDH1A1 | |
| SCHEMBL3408772 | 0.73 | ALOX5 (0.41) | KDM4ETRPM8ALDH1A1 | |
| SCHEMBL16791622 | 0.72 | ALDH1A1 (0.41) | LMNANPSR1SMN1; SMN2HTTHPGD | |
| SCHEMBL13637077 | 0.72 | ALDH1A1 (0.41) | LMNANPSR1KDM4ESMN1; SMN2HTT | |
| SCHEMBL13953697 | 0.71 | ALOX5 (0.37) | HTTTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | PURDUE RESEARCH FOUNDATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | PURDUE RESEARCH FOUNDATION (US) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | HBB, BCAT1, BCAT2 | LMNA 502/4885NPSR1 1640/4885KDM4E 4642/4885 |
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | HBB, BCAT1, BCAT2 | LMNA 712/4885NPSR1 1124/4885KDM4E 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.